2022
DOI: 10.1016/j.mpaic.2022.02.014
|View full text |Cite
|
Sign up to set email alerts
|

An update of systemic analgesics in children

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 22 publications
0
1
0
Order By: Relevance
“…Tuning the area (1 cm 2 and 2 cm 2 or 6 cm 2 ) of the optimized formulation (Formulation F13, Table 3), it would be possible to make available personalize dosage forms to manage acute migraines [27] and pain [28,29] in pediatric patients. This aspect could be of interest for children, since to the best of our knowledge, there is no commercially available pediatric dosage form (e.g., syrup or suspension) of DNa due to its stability issues.…”
Section: Accelerated Stability Studymentioning
confidence: 99%
“…Tuning the area (1 cm 2 and 2 cm 2 or 6 cm 2 ) of the optimized formulation (Formulation F13, Table 3), it would be possible to make available personalize dosage forms to manage acute migraines [27] and pain [28,29] in pediatric patients. This aspect could be of interest for children, since to the best of our knowledge, there is no commercially available pediatric dosage form (e.g., syrup or suspension) of DNa due to its stability issues.…”
Section: Accelerated Stability Studymentioning
confidence: 99%